3) patients with a pathologic non-response (pNR =  > 50% viable tumor cells) would undergo both a TLND in a second surgery, as well as adjuvant systemic therapy (either switch to BRAF/MEK inhibition for BRAF mutant melanomas or continuation of anti-PD-1) ± adjuvant radiotherapy to the node field [58••]. The gene discussed is BRAF; the disease is neoplasm.